Satellos Bioscience Inc.

TSX:MSCL.TO

Biotechnology

Healthcare
$8.62 +0.12%

+$0.01 today

Market cap
$182.89M
Beta
1.17
P/E (TTM)
-1.8
EPS (TTM)
-$0.32
52W Low $6.36High $18.98

Volume 0.01M

Average 0.02M

MSCL.TO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Satellos Bioscience Inc.TSX: MSCL.TO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows 56.5% year over year

Q1 FY2026 net income of $9.61M (cash outflow) rose 56.5% year over year. Sequentially, it rose 29.6% from the prior quarter. Over 3 fiscal years it compounded at +30.8% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate of -$32.91M (+30.0%) for the fiscal year ending Dec 2026, a step up from the -9.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$9.61M+29.6% QoQ
Last fiscal yearDec 2025
-$25.31M-9.9% YoY
LTMMar 2026
-$28.45M— YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+56.5%+67.6%+11.1 pp
1 year-9.9%+30.0%+40.0 pp
3-year CAGR+30.8%+5.5%-25.2 pp
5-year CAGR-18.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

Mixed currencies · from the cash flow

Latest · FY2025
(25.31M) USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How MSCL.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Over three fiscal years its annual growth of +30.8% compares with a peer median of -7.4%.
MSCL.TO Competitors
Net Income for MSCL.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$36.35M CAD+1.6%+3.0%—
MSCL.TOSatellos Bioscience Inc.LTM Mar 2026$28.45M USD—+30.8%—
SVA.TOSernova Corp.LTM Apr 2026CA$11.83M CAD-46.2%-13.6%—
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$3.32M CAD-65.1%-7.4%—
Peer median (excluding MSCL.TO) —-46.2%-7.4%—

Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · CAD
FY2024
Dec 2024 · CAD
FY2025
Dec 2025 · USD
Net Income(15.51M)(11.32M)(15.89M)(28.1M)(25.31M)
Depreciation & Amortization165.69K337K7K20K4K
Deferred Income Tax00000
Stock-Based Compensation971.53K1.44M2.17M2.11M3.24M
Change in Working Capital(485.64K)991K369K(1.03M)(1.5M)
Accounts Receivables(67.4K)267.55K(323K)(43K)66.14K
Inventory00000
Accounts Payables(390.47K)726.11K000
Other Working Capital(27.77K)(1.93K)692K(982K)(1.57M)
Other Non-Cash Items9.82M2.91M(1.07M)2.02M(435.77K)
Operating Cash Flow(5.03M)(5.78M)(14.5M)(24.98M)(24.01M)
Capital Expenditures(7.25K)(3K)(18K)(6K)(6.1K)
Acquisitions (Net)1.75M0000
Purchases of Investments00(17.52M)(37.34M)(23.78M)
Sales of Investments00043.68M14.2M
Other Investing Activities00000
Investing Cash Flow1.74M(3K)(17.54M)6.34M(9.58M)
Debt Repayment186.57K0(284K)00
Common Stock Issued7.08M2.78M32.46M42.8M2.28M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities185.46K018.85M10.68M0
Financing Cash Flow7.45M2.78M51.03M53.49M2.28M
Effect of Forex Changes(1.44K)(76K)1.15M744K(890.45K)
Net Change in Cash4.15M(2.95M)20.14M35.59M(32.2M)
Free Cash Flow(5.04M)(5.79M)(14.52M)(24.98M)(24.02M)

Satellos Bioscience Inc.

TSX:MSCL.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.